香港联交所最新资料显示，11月11日，执行董事杨建新增持基石药业(02616)10万股，每股均价5.345港 元，总金额为53.45万港元。增持后最新持股数目约为7126.27万股，最新持股比例4.83%。 ...

智通财经APP获悉，香港联交所最新资料显示，11月11日，执行董事杨建新增持基石药业(02616)10万 股，每股均价5.345港元，总金额为53.45万港元。增持后最新持股数目约为7126.27万股，最新持股比例 4.83%。 ...

Core Viewpoint - The company will showcase its pipeline asset CS2015, a dual-specific antibody targeting OX40L and TSLP, at the 2025 ACAAI annual scientific meeting, marking its international debut [1] Group 1: Company Developments - CS2015 is designed with an asymmetric molecular structure that targets two key regulatory factors effective in blocking type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, aiming to extend its in vivo circulation half-life and optimize pharmacokinetic characteristics for prolonged dosing intervals [1] - The stability of CS2015 supports the development of high-concentration subcutaneous formulations, while its excellent developability lays the foundation for high-yield and large-scale production [1] Group 2: Industry Context - The ACAAI is recognized as one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting numerous experts and scholars globally to discuss the latest research findings [1]

Core Viewpoint - Company will showcase its pipeline asset CS2015 at the 2025 ACAAI annual scientific meeting, marking its first appearance at an international academic conference [1] Group 1: Company Developments - CS2015 is a bispecific antibody targeting OX40L and TSLP, which are key regulatory factors that effectively block type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, aiming to extend its in vivo circulation half-life and optimize pharmacokinetic (PK) characteristics for prolonged dosing intervals [1] - CS2015 demonstrates excellent molecular stability, supporting the development of high-concentration subcutaneous formulations [1] Group 2: Industry Context - ACAAI is one of the most influential academic conferences in the field of allergy, asthma, and immunology, attracting experts from around the world to discuss the latest research findings [1] - The complete abstract and electronic poster for CS2015 have been officially published on the ACAAI website [1]

Core Viewpoint - Company will showcase its pipeline asset CS2015 at the upcoming ACAAI annual scientific meeting in 2025, marking its first appearance at an international academic conference [1] Group 1: Company Developments - CS2015 is a bispecific antibody targeting OX40L and TSLP, which are key regulators that effectively block type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, thereby extending its half-life in circulation and optimizing pharmacokinetic (PK) characteristics for prolonged dosing intervals [1] - CS2015 demonstrates excellent molecular stability, supporting the development of high-concentration subcutaneous formulations and ensuring scalability for production [1] Group 2: Industry Context - ACAAI is one of the most influential academic conferences in the field of allergy, asthma, and immunology, attracting experts from around the world to discuss the latest research findings [1] - The complete abstract and electronic poster for CS2015 have been officially published on the ACAAI website, enhancing visibility within the scientific community [1]

(股份代號：2616) 自願 公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前 瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任 何前瞻性陳述及預料之外的事件。請細閱本公告，並理解我們的實際未來業績或表現可能與預期有 重大差異。本公告中有關我們或任何董事及╱或本公司的意向的陳述或提述乃於本公告刊發日期作 出。任何該等意向均可能因未來發展而出現變動。 CStonePharmaceuticals 基石藥業 ( 於開曼群島註冊成立的有限公司 ) ACAAI 2025 | CS2015（OX40L/TSLP雙特異性抗體）首次亮相國際學術舞臺 本公告乃由基石藥業(「本公司」連同其附屬公司統稱「本集團」或「基石藥業」)自願作出， 以使本公司股東及潛在投資者瞭解本集團的最新業務發展。 …………………………………………………………………… ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年10月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 基石藥業 | | | | | | 呈交日期: | 2025年11月6日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02616 | 說明 | | | | | 上月底結存 | 2,000,000,000 | USD | 0.0001 | USD | 200,000 | | --- | --- | --- | --- | --- | --- | | 增加 / 減少 (-) | 0 | | | USD | 0 | | 本月底結存 | 2,000,000,000 | USD | 0.0001 | USD | 200,000 | 本月底法定/註冊股本總 ...

Core Viewpoint - The company announced the approval of its clinical trial application for CS2009, a novel tri-specific antibody targeting PD-1, VEGFA, and CTLA-4, for use in late-stage solid tumors by the National Medical Products Administration (NMPA) of China [1] Group 1 - CS2009 is developed independently by the company from molecular design [1] - The tri-specific antibody aims to achieve multi-dimensional anti-tumor effects through synergistic action [1]

Core Viewpoint - 基石药业-B (02616.HK) has received approval from the National Medical Products Administration (NMPA) in China for the clinical trial application of CS2009, a PD-1/VEGF/CTLA-4 tri-specific antibody, for use in advanced solid tumors [1] Group 1: Clinical Trial Details - The Phase I study of CS2009 has provided significant confidence to the company, prompting the acceleration of the Phase II study [1] - The Phase II clinical trial will adopt a multi-cohort parallel expansion design, covering 15 monotherapy/combinational therapy cohorts across 9 solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [1] - The Phase II clinical trial is currently actively enrolling participants in Australia, and the approval of the IND in China will further expedite the clinical development process [1] Group 2: Company Leadership - Dr. Yang Jianxin, CEO, President of R&D, and Executive Director of the company, expressed optimism regarding the therapeutic potential of CS2009 based on the initial data from the Phase I study [1]

Core Viewpoint - The approval of the IND for CS2009, a tri-specific antibody therapy, marks a significant advancement for the company in the treatment of advanced solid tumors, indicating strong confidence in its clinical development potential [1] Company Summary - The company announced that its CS2009 therapy, which targets PD-1, VEGF, and CTLA-4, has received approval for a Phase II clinical trial in China [1] - The CEO, Dr. Yang Jianxin, expressed confidence in accelerating the Phase II study based on promising preliminary data from the Phase I trial [1] - The Phase II trial will utilize a multi-cohort parallel expansion design, covering 15 monotherapy and combination therapy cohorts across 9 solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [1] - The trial is currently enrolling participants in Australia, and the approval in China is expected to expedite the clinical development process [1]